| Advances in phenotypic screening |
|---|
| • High throughput screening |
| • Advanced data analysis |
| • Access to patient-derived samples |
| • Organoids |
| • Pluripotent stem cell technologies |
| • Gene-editing tools (CRISPR–Cas) |
| Advances in phenotypic screening |
|---|
| • High throughput screening |
| • Advanced data analysis |
| • Access to patient-derived samples |
| • Organoids |
| • Pluripotent stem cell technologies |
| • Gene-editing tools (CRISPR–Cas) |